文献速递产科母胎医学

为高危产科患者提供现场新冠疫苗接种的初步发现

Offering onsite COVID-19 vaccination to high-risk obstetrical patients: initial findings.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-09-02

该质量改进项目在单一学术医疗中心的两个高危产科门诊开展,比较现场提供BNT162b2 mRNA疫苗接种前后4周内93名患者的接种率。结果显示,现场接种可用前后接种率分别为3%和11%,差异无统计学意义(P=.22),仅3%的合格患者接受现场接种,提示疫苗犹豫而非可及性是低接种率的关键驱动因素。

要点

  • 现场提供疫苗接种未显著提高高危产科患者的接种率(3% vs 11%,P=.22)。
  • 仅3%的合格患者接受现场接种,研究期间总接种率14%,远低于同期密苏里州41%的接种率。
  • 疫苗犹豫可能是低接种率的关键因素,需进一步评估和干预。

核心结论

  • 在高危产科患者中,现场提供疫苗接种未显著提高接种率,疫苗犹豫而非可及性可能是低接种率的关键驱动因素。

研究设计与样本

  • 单中心学术医疗中心的质量改进项目,在两个高危产科门诊开展,数据收集4周(2021年4月27日至5月20日),共93名患者、124次就诊。
  • 现场接种于2021年5月11日开始,比较接种可用前4个门诊日与可用后4个门诊日的接种率。

主要发现

  • 现场接种可用前,32名合格患者中1名(3%)在外部接种;可用后,55名合格患者中2名(3%)接受现场接种,另4名(7%)在外部接种。
  • 现场接种可用前后接种率分别为3%和11%,差异无统计学意义(P=.22)。
  • 在仅于现场接种期间就诊的25名合格患者中,无人接受现场接种或寻求外部接种。
  • 研究期间总接种率为14%,而同期密苏里州报告接种率为41%。

临床怎么用

  • 仅增加疫苗可及性可能不足以提高产科患者的接种率,即使经过专家临床咨询。
  • 重复门诊就诊和建立信任关系可能是疫苗决策的重要环节,早期干预或有助于提高接种率。

局限性

  • 研究为前后比较设计,期间疫苗接种建议和人群情绪快速演变,可能存在偏倚。
  • 样本量较小,可能不足以显示统计学差异。
  • 单一临床环境限制了其他偏倚来源,但结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The COVID-19 pandemic has had a disproportionate effect on pregnant women, with higher rates of viral infection and disease severity.1 The development of highly effective vaccines has significantly reduced SARS-CoV-2 transmission and clinical disease.2 However, vaccine uptake has been low in the pregnant population.3 The Centers for Disease Control and Prevention guidance suggests that limited vaccine access, not vaccine hesitancy, has driven the lower uptake rates in at-risk populations.4 We describe our experience with vaccination uptake rates among high-risk obstetrical patients before and after onsite BNT162b2 messenger RNA vaccination availability in outpatient clinics as part of a pilot program to improve vaccine access among pregnant patients. STUDY DESIGN: This was a quality improvement project at a single academic medical center. Onsite vaccination was available once a week at 2 high-risk obstetrical clinics staffed by obstetrical residents, maternal-fetal medicine (MFM) fellows, and MFM attendings were selected for our vaccine pilot program. Onsite vaccinations were immediately available for use in the clinic starting May 11, 2021. Data were collected over a 4-week period (April 27, 2021, to May 20, 2021), which included 4 clinic days before onsite vaccine availability (April 27, 2021 to May 10, 2021) and 4 days with onsite vaccine availability (May 11, 2021, to May 20, 2021). Patients were considered exposed to onsite vaccination if they had any clinic visits during the latter 2 weeks of the study period. All patients were counseled by providers at each visit using our institution's standardized COVID-19 vaccination discussion tool designed for pregnant and breastfeeding patients.5 Counseling was documented in each patient's chart per the American College of Obstetricians and Gynecologists. Before and throughout the study period, pregnancy was listed as a qualifying condition for priority vaccination in Missouri and Illinois. At this time, vaccinations were readily available in the local area surrounding our clinical space. Data on vaccine administration were collected via the Missouri and Illinois state databases over a period of 1 month after the pilot program was closed, allowing for the collection of data on patients who pursued vaccination offsite for scheduling or personal reasons. This project was deemed exempt by the Office for Human Research Protections. RESULTS: We reviewed data from 124 clinic visits, where a total of 93 individual patients were seen in the 4-week period; 6 had previously been vaccinated at external sites and the remaining 87 were eligible (Figure). The majority of our patient population was non-Hispanic Black women with public or no insurance (Table). Of the 32 eligible patients seen and counseled before onsite vaccination availability, 1 (3%) proceeded to receive the vaccination offsite. Of the 55 eligible patients seen and counseled after onsite vaccination availability, 2 (3%) proceeded with onsite vaccination and an additional 4 (7%) proceeded with vaccination offsite. Onsite vaccination availability did not significantly increase the vaccination rates (3% vs 11%; P=.22). Of the 55 eligible patients counseled during onsite vaccination availability, 25 were seen and counseled exclusively during the onsite vaccination pilot period and none of these patients accepted onsite vaccination or pursued vaccination offsite. CONCLUSION: Because only 3% of eligible, high-risk obstetrical patients proceeded with onsite vaccination, our experience suggests that vaccine hesitancy, not availability, is a critical driver of the low vaccination rates in this population. Although a larger sample size may have demonstrated statistical difference, the overall low vaccination uptake rate forced the closure of our pilot program over concerns for wasted vaccination doses. In a population at high risk for progression to severe COVID-19, only 14% of our study population was vaccinated, whereas Missouri reported a 41% vaccination rate during this time.6 These findings suggest that increased access alone may not improve vaccination rates in obstetrical patients even after counseling by expert clinicians. These findings are limited by the pre/post nature of the comparison, exposing the sample to bias as vaccination recommendations and population sentiment was rapidly evolving during this time period. However, the consistency of counseling and patient population provided by a single clinical setting limited other sources of bias during the study period. Vaccine hesitancy is multifactorial and complex and urgently requires more evaluation in this high-risk population. Vaccine hesitancy in pregnancy is well documented, but early reports suggest that the COVID-19 vaccination uptake rate is markedly lower than that of other vaccines during pregnancy. Our finding that none of the women who were seen exclusively during the onsite vaccination period accepted vaccination may suggest that repeat clinic visits and the associated establishment of rapport and trust is a vital part of vaccine decision making. Earlier intervention, before patient views on novel therapeutics such as vaccinations can be formulated and fixed, may aid in uptake. Further qualitative work and inclusion of pregnant women in vaccine trials is an initial step.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Hirshberg JS, Huysman BC, Oakes MC, et al. Offering onsite COVID-19 vaccination to high-risk obstetrical patients: initial findings. Am J Obstet Gynecol MFM. 2021. PMID: 34481996. doi:10.1016/j.ajogmf.2021.100478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。